Men's Health & Endocrinology · Evidence-Based Research · May 2026
Millions of men are living with fatigue, depression, weight gain, and fading desire — not because they are lazy or weak, but because a hormone that defines male physiology is disappearing. Here is the full picture, from biology to bedside.
There is a particular kind of exhaustion that doctors struggle to explain on a standard blood panel. A man sits across from his physician and describes something that sounds like a dozen different conditions at once — low energy that a good night's sleep doesn't fix, a fading interest in sex that he attributes to stress, a thickening around his waist despite a reasonably active lifestyle, and a fog that sits over his concentration like weather that will not break. He is told he is getting older. He is told to exercise more. Sometimes he is handed a prescription for an antidepressant. What he is rarely told is that a single hormone may be quietly responsible for much of what he feels.
That hormone is testosterone. And according to data compiled by the Urology Care Foundation, an estimated 4 to 5 million men in the United States are living with hypogonadism — the clinical name for testosterone deficiency — though many more go undiagnosed and untreated. The Hypogonadism in Males (HIM) study, one of the most comprehensive epidemiological reviews on the subject, placed the crude prevalence rate at 38.7% in men over 45 who visited primary care practices. Of those, the vast majority had never received a diagnosis.
To understand what this means in human terms, it helps to first understand what testosterone actually does. It is not, as popular culture suggests, merely the hormone that drives aggression or libido. It is a master regulator. Produced primarily in the Leydig cells of the testes, with smaller amounts synthesized in the adrenal glands, testosterone governs an extraordinary range of biological functions: muscle mass, bone density, red blood cell production, mood regulation, cognitive sharpness, fat distribution, insulin sensitivity, cardiovascular health, and sexual function. When levels fall significantly below the threshold the American Urological Association defines as normal — 300 nanograms per deciliter (ng/dL) — the consequences ripple through virtually every organ system in the body.
The condition is divided by mechanism into two broad categories. Primary hypogonadism originates in the testes themselves — the glands fail to produce adequate testosterone despite receiving proper hormonal signals from the brain. This can result from genetic conditions like Klinefelter syndrome, physical injury, viral infections such as mumps orchitis, or treatments like chemotherapy and radiation. Secondary hypogonadism — also called hypogonadotropic hypogonadism — occurs when the problem lies upstream, in the hypothalamus or pituitary gland. The brain simply does not send the right signals. And then there is a third, increasingly recognized category: age-related or late-onset hypogonadism, which occurs when the testes gradually lose their capacity to respond to hormonal stimulation as a man ages. This is where the epidemiological story becomes both compelling and alarming.
The most unsettling finding in recent testosterone research is not that individual men age and see their hormones decline — that has always been true, and testosterone does naturally begin to decrease by roughly 1 to 2% per year after the age of 30. What is alarming is that large-scale population studies now confirm an age-independent, generational decline in testosterone levels across the developed world. A man in his 40s today has measurably lower testosterone than a man of the same age in 1990. This is not a function of individual aging — it is something happening to men as a group, across entire populations.
A 2025 harmonization effort across 50 cohorts confirmed this decline survives methodological correction, and a 2020 Israeli study that reanalyzed historical samples using modern liquid chromatography-mass spectrometry — more precise than earlier assays — confirmed a genuine 22% true drop unrelated to measurement error. Research at Spital Clinic London attributes this generational trend to a constellation of lifestyle and environmental forces that have fundamentally restructured male physiology over the last half-century.
The lifestyle contributors are substantial and largely modifiable. Research consistently shows that the average testosterone levels in men have been declining for decades, driven in part by the dramatic shift from physically demanding labor to sedentary desk work. A man working a physically demanding job in the 1970s would have had a very different hormonal profile from a man of the same age spending eight hours a day at a computer screen. Physical exertion is one of testosterone's most reliable natural stimulants, and its absence has consequences. A 2023 meta-analysis attributed 40% of low-testosterone cases to modifiable lifestyle factors, and a subsequent 12-week intervention trial found that resistance training combined with a Mediterranean-style diet raised testosterone levels by 20% in overweight men.
Obesity plays a particularly vicious role. Adipose tissue — body fat — contains an enzyme called aromatase, which converts testosterone into estrogen. The more body fat a man carries, especially visceral abdominal fat, the more his available testosterone is enzymatically converted away. The HIM study found that obese men had 2.38 times higher odds of having hypogonadism compared to men without obesity. Men with diabetes showed 2.09 times higher odds. The bidirectional nature of the relationship makes it clinically complex: low testosterone promotes fat storage and insulin resistance, which in turn suppress testosterone further. Breaking that cycle requires deliberate intervention.
Sleep is another underappreciated pillar. Research has demonstrated that sleeping fewer than five hours per night can reduce testosterone levels by 10 to 15% in healthy young men. The vast majority of testosterone secretion occurs during sleep — primarily during the REM and deep slow-wave stages. The proliferation of smartphones, constant digital connectivity, and the cultural normalization of sleep deprivation has disrupted the hormonal architecture of millions of men who have no idea why they feel the way they do. Chronic psychological stress compounds this effect through cortisol. When the body's primary stress hormone remains chronically elevated, it suppresses the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal communication pathway responsible for triggering testosterone production — creating yet another feedback loop that is difficult to interrupt without addressing root causes.
Then there are the environmental factors that are harder to control. Endocrine-disrupting chemicals (EDCs) — found in plastics, pesticide residues, personal care products, non-stick cookware coatings, and food packaging — act as hormonal imposters. BPA (bisphenol A), phthalates, PFAS compounds, and agricultural herbicides like atrazine can mimic estrogen, block androgen receptors, and interfere directly with the HPG axis. A 2024 meta-analysis of 45 animal studies found these effects at environmentally relevant doses. Human data tells a similar story: farmworkers with high atrazine exposure show 15 to 20% lower testosterone and elevated estrogen levels. Together, EDCs may account for as much as 10 to 20% of the generational testosterone decline observed in population studies.
What does this mean in daily life? The symptoms of hypogonadism are both broad and deeply personal, which is part of why the condition remains so underdiagnosed. According to the Cleveland Clinic, testosterone levels begin declining approximately 1% per year starting in the late 30s. By the time symptoms become significant, many men have normalized what they are experiencing. The symptoms themselves span a wide spectrum: reduced libido, erectile dysfunction, decreased ejaculate volume, loss of body and facial hair, increased body fat particularly around the midsection, reduced lean muscle mass despite regular exercise, fatigue that is disproportionate to exertion, difficulty concentrating, irritability, and low mood that shades into clinical depression. UT Southwestern Medical Center estimates that approximately 35% of men in their 70s have clinically low testosterone, and notes a growing number of men in their 20s presenting with low-T — a demographic shift that was not observed two decades ago.
- Persistently low energy and fatigue unrelieved by sleep
- Decreased sex drive and erectile dysfunction
- Loss of muscle mass and strength despite exercise
- Increased body fat, especially abdominal
- Depression, irritability, or difficulty concentrating
- Reduced bone density (osteopenia or osteoporosis)
- Anemia and reduced red blood cell production
- Hot flashes, night sweats (less common but recognized)
- Decreased beard and body hair growth
- Reduced testicular size or volume
The skeletal consequences are particularly underappreciated by men who associate osteoporosis primarily with post-menopausal women. Testosterone is critical for maintaining bone mineral density in men, and its deficiency is a major risk factor for bone thinning. A 2025 retrospective cohort study published in the Journal of Urology analyzing data from 15,634 patients with hypogonadism found that men with osteoporosis had 1.37 times higher odds of also having hypogonadism compared to those with osteopenia alone. Despite this strong clinical association, routine testosterone screening in men presenting with low bone density remains uncommon — a gap the study's authors describe as a missed diagnostic opportunity.
The cardiovascular dimension of testosterone deficiency has generated substantial and sometimes contentious debate in the medical literature. Research published in PMC has established that low serum testosterone is closely associated with the development of atherosclerosis — the arterial plaque buildup that underlies heart attacks and strokes. Low testosterone correlates with central obesity, insulin resistance, dyslipidemia, and hypertension — together constituting metabolic syndrome, which is itself a major cardiovascular risk multiplier. The directionality of this relationship continues to be studied, but several randomized controlled trials have shown that testosterone replacement treatment significantly decreases insulin resistance, suggesting that correction of the hormonal deficiency can disrupt the metabolic cascade that drives cardiovascular risk.
The neurological and psychological effects are equally significant and frequently dismissed. Testosterone influences the production and regulation of dopamine and serotonin — neurotransmitters central to mood, motivation, and reward processing. A 2017 review found that testosterone replacement therapy significantly improved depression symptoms and overall quality of life in men with confirmed low testosterone. Men with untreated hypogonadism show higher rates of depression and anxiety — conditions that have risen sharply among younger men in recent years. What clinicians and mental health professionals sometimes miss is that for a subset of these men, the depression is not primarily psychological in origin. It is endocrine. Treating the hormone can move the needle in ways that therapy or medication alone cannot.
Diagnosis requires more than a single testosterone reading. Because testosterone levels fluctuate throughout the day — peaking in the early morning and declining through the afternoon — clinical guidelines recommend that blood be drawn between 7 and 10 a.m. on at least two separate occasions before a diagnosis is made. The American Urological Association defines low testosterone as a total serum level below 300 ng/dL, accompanied by symptoms. Free testosterone — the fraction not bound to proteins in the blood and therefore biologically active — can provide additional diagnostic clarity, particularly in men whose total testosterone sits in a borderline range. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels help distinguish primary from secondary hypogonadism. A complete picture also includes prolactin, thyroid function, complete blood count, and metabolic panels, since many conditions can coexist with or mimic testosterone deficiency.
Once diagnosed, the treatment landscape for hypogonadism has expanded considerably over the past decade, and public awareness — driven partly by direct-to-consumer advertising and the rise of telehealth platforms — has fueled a dramatic increase in prescribing. TRT prescriptions in the United States increased from 7.3 million in 2019 to over 11 million in 2024. In 2022 alone there was a 27% increase in testosterone therapy patients, with the sharpest rise — 58% — among men aged 35 to 44. The global testosterone replacement therapy market was valued at approximately $1.9 billion in 2024 and is projected to reach $2.9 billion by 2034.
The forms of delivery are varied and have different pharmacological profiles. Intramuscular injections of testosterone cypionate or enanthate remain widely used for their cost-effectiveness and established long track record, though they produce peaks and troughs in serum levels that some men find difficult to tolerate emotionally and physically. Transdermal gels applied daily to the skin produce steadier levels and are now among the most commonly prescribed formulations. Testosterone pellets — small implants inserted under the skin of the buttock — release the hormone slowly over three to six months and have attracted a loyal following among men who prefer to avoid daily application. Oral testosterone undecanoate, available in some markets, has improved considerably over older oral formulations that were associated with hepatotoxicity. The 2024 Fifth International Consultation on Sexual Medicine consensus paper on male hypogonadism reviewed the full evidence base for these options and emphasized individualized treatment selection based on patient preferences, comorbidities, and fertility intentions.
Fertility is a critical consideration that is often overlooked in discussions of testosterone therapy. Exogenous testosterone — testosterone from outside the body — suppresses the brain's natural signaling to the testes, effectively halting sperm production. For men who wish to preserve or restore fertility, alternative approaches such as clomiphene citrate, human chorionic gonadotropin (hCG), or aromatase inhibitors are often used instead of or alongside direct testosterone replacement. These agents stimulate the body's own testosterone production rather than bypassing it, preserving the testicular function necessary for spermatogenesis. This distinction matters enormously for younger men presenting with low testosterone who may not yet have completed their families — a conversation that does not always happen in a rushed clinical visit.
The safety debate around testosterone replacement therapy deserves honest engagement. The FDA has required that testosterone drug labels carry warnings about potential cardiovascular risks, including heart disease and stroke. This followed earlier observational studies that suggested elevated risk in some populations. However, more rigorous subsequent research has substantially complicated that picture. A comprehensive 2024 health technology assessment — the TestES evidence synthesis commissioned by the UK's National Institute for Health and Care Research — found that testosterone replacement therapy improved quality of life and sexual function in almost all patient subgroups, and noted that meaningful evaluation of cardiovascular mortality was hampered by limited event numbers in existing trials. The AUA itself has stated there is no strong evidence that TRT either increases or decreases the risk of cardiovascular events, while acknowledging that all men should be screened for cardiovascular risk before beginning therapy.
For men who are not yet at the threshold for pharmacological intervention, or who prefer to exhaust natural approaches first, the evidence for lifestyle modification is genuinely encouraging. Regular resistance training — the kind that challenges large muscle groups with progressive overload — is one of the most potent natural stimulants of testosterone production. Increased physical activity consistently shows an inverse relationship with low testosterone risk. Diet quality matters too: diets high in refined carbohydrates, ultra-processed foods, and trans fats are associated with lower testosterone, while diets rich in healthy fats, zinc, magnesium, vitamin D, and lean protein support hormonal synthesis. Zinc — found in abundance in red meat, shellfish, seeds, and legumes — is a cofactor in testosterone production; its deficiency is associated with hypogonadism even in otherwise healthy young men.
Reducing alcohol consumption is important and frequently underemphasized. Chronic alcohol use suppresses the HPG axis, reduces testicular response to LH, and elevates estrogen conversion. Even moderate regular drinking can meaningfully reduce free testosterone in men over 40. Weight loss — specifically the reduction of visceral fat — decreases aromatase activity and can produce clinically meaningful rises in testosterone without any pharmacological intervention. Approximately 30% of obese men have clinically low testosterone, and in many of them, sustained weight loss will restore levels to the normal range. Prioritizing sleep — specifically seven to nine hours of quality, uninterrupted sleep — restores the nocturnal testosterone surge that modern sleep habits routinely interrupt. And managing chronic stress through exercise, mindfulness, social connection, or professional support reduces cortisol's inhibitory grip on the HPG axis.
The conversation around testosterone is also beginning — slowly — to acknowledge its relevance in women. While women produce far less testosterone than men, the hormone is nonetheless critical to female libido, energy, mood, and bone density. Women with low testosterone — often overlooked because it falls outside conventional gynecological focus — can experience fatigue, low sexual desire, depression, and muscle weakness that mirror male hypogonadal symptoms almost exactly. Research into female testosterone deficiency remains underfunded compared to its male equivalent, but clinical interest is growing, and some endocrinologists are now beginning to routinely screen women in perimenopausal and postmenopausal states for testosterone deficiency alongside estrogen and progesterone evaluation.
What this entire body of evidence points to is something that medicine has been slow to communicate clearly: testosterone is not a lifestyle supplement for the gym-obsessed or a chemical shortcut for men who want to avoid aging gracefully. For men with genuine hypogonadism — confirmed biochemically and clinically — it is a treatment for a hormone deficiency with cascading health consequences. The challenge is precision: diagnosing the condition accurately, treating the underlying causes where possible, and applying pharmacological intervention where the biology genuinely requires it. Approximately 40% of men under 40 have expressed interest in testosterone supplementation, and nearly 14% are using or have previously used TRT — figures that suggest the pendulum may be swinging too far in the direction of casual self-treatment.
The solution lies not in overcorrection in either direction — neither in the reflexive dismissal of low testosterone as mere aging, nor in the indiscriminate prescribing that now characterizes parts of the telehealth industry. It lies in actually listening to the men who present with fatigue that will not lift, desire that will not return, and confidence that has slowly, quietly, without any single dramatic event, begun to disappear. It lies in running the right tests, having honest conversations about risk and benefit, and recognizing that for millions of men, the answer to a question they have been too embarrassed to ask properly may be written not in their psychology or their choices, but in their blood.
- Normal testosterone range (adults):300–1,000 ng/dL; young adults typically 600–900 ng/dL
- Diagnostic threshold for low-T:Below 300 ng/dL (AUA definition)
- Age-related decline:~1% per year starting around age 30
- Prevalence in men over 45:38.7% by HIM study criteria
- Men over 65 with low free testosterone:More than 60%
- Obesity & low-T link:~30% of obese men have low testosterone
- Generational decline:~22% true drop confirmed by standardized assay re-analysis
Sources & Further Reading: HIM Study – PMC (Hypogonadism prevalence in men 45+) · Urology Care Foundation – Low Testosterone · ICSM 2024 Hypogonadism Consensus – Oxford Academic · TestES Evidence Synthesis – NIHR 2024 · Secular Testosterone Decline Review – MDPI 2026 · Cleveland Clinic – Male Hypogonadism · Low Testosterone Statistics 2026 – SingleCare
This article is for informational purposes only and does not constitute medical advice. Men experiencing symptoms of low testosterone should consult a qualified healthcare provider for personalized evaluation and treatment.
0 Comments